GlassScriptPhysician profile
Christopher V Poole
NPI 1558368837
$1,925.58
in general payments reported to CMS, 2019-2025
21 companies · $961 in 2025
The $961 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $76.53 · 2021: $90.71 · 2022: $313 · 2023: $13.22 · 2024: $225 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709 · Honoraria: $450 · Education: $40.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.63 |
| Honoraria | $450.00 |
| Education | $40.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $468.73 | 2025 | Elfabrio |
| Astrazeneca Pharmaceuticals LP | $263.89 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $241.20 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $221.89 | 2024-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $155.38 | 2022-2024 | Lupkynis |
| Novo Nordisk INC | $97.03 | 2024-2025 | Ozempic |
| Genzyme Corporation | $93.93 | 2024-2025 | |
| Amgen INC. | $85.53 | 2022 | |
| Mallinckrodt Hospital Products INC. | $71.58 | 2022-2025 | Terlivaz, Acthar |
| Vifor Pharma, INC. | $42.38 | 2019-2020 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Travere Therapeutics, INC. | $24.04 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.03 | 2020 | |
| Glaxosmithkline, LLC. | $16.80 | 2019 | |
| Genentech USA, INC. | $15.98 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $15.94 | 2022 | |
| Opko Pharmaceuticals, LLC | $15.18 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.50 | 2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $13.76 | 2024 | Crysvita |
| Mallinckrodt Enterprises LLC | $13.18 | 2019 | |
| Medtronic Vascular, INC. | $13.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Poole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.